What is Roth Capital’s Estimate for Enovis Q1 Earnings?

Enovis Co. (NYSE:ENOV) – Equities researchers at Roth Capital issued their Q1 2025 EPS estimates for Enovis in a report issued on Thursday, February 27th. Roth Capital analyst J. Wittes forecasts that the company will earn $0.73 per share for the quarter. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.88 EPS.

Separately, Needham & Company LLC dropped their price target on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Price Performance

ENOV opened at $36.62 on Monday. The firm has a market capitalization of $2.09 billion, a P/E ratio of -16.72 and a beta of 1.94. The stock has a fifty day moving average of $44.61 and a 200-day moving average of $44.24. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis has a 12-month low of $35.14 and a 12-month high of $63.96.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company’s stock valued at $240,731,000 after acquiring an additional 75,348 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock valued at $129,352,000 after purchasing an additional 218,660 shares during the last quarter. DAVENPORT & Co LLC grew its stake in Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after purchasing an additional 157,216 shares in the last quarter. Royce & Associates LP increased its position in Enovis by 2.8% in the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock worth $108,409,000 after purchasing an additional 66,891 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Enovis by 4.3% during the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company’s stock worth $70,913,000 after purchasing an additional 68,190 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.